RAPP — Rapport Therapeutics, Inc.

Ownership history in JOHNSON & JOHNSON  ·  7 quarters on record

This page tracks every 13F SEC filing in which JOHNSON & JOHNSON reported a position in Rapport Therapeutics, Inc. (RAPP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
14.5% (2024 Q2)
Avg. % of fund
10.59%
First filed
2024 Q2
Last filed
2025 Q4
Quarters held
7
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 1,784,517 — 0% 9.76% $54.1M $30.34
2025 Q3 REDUCED 1,784,517 -713,534 -28.6% 10.52% $53.0M $29.70
2025 Q2 UNCHANGED 2,498,051 — 0% 8.55% $28.6M $11.37
2025 Q1 UNCHANGED 2,498,051 — 0% 7.33% $25.1M $10.03
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    RAPP price (monthly, adj. close)

Other funds also holding RAPP

As of 2025 Q4 — sorted by position size

TRV GP V, LLC 50.44% TRV GP VI, LLC 19.8% ARCH Venture Management, LLC 3Y 7Y 17.36% Cormorant Asset Management, LP 3Y 7Y 4.25% Sofinnova Investments, Inc. 3Y 7Y 2.49% Vestal Point Capital, LP 1.14% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 0.95% Sio Capital Management, LLC 3Y 7Y 0.88% Siren, L.L.C. 0.64% Artia Global Partners LP 3Y 0.6%
← Back to JOHNSON & JOHNSON Holdings